iStockAxis Securities has buy call on Krishna Institute of Medical Sciences with a target price of Rs 1450.
The current market price of Ltd. is Rs 1204.1.
Time period given by analyst is one year when Krishna Institute of Medical Sciences Ltd. price can reach defined target.
Krishna Institute of Medical Sciences Ltd., incorporated in the year 1973, is a Small Cap company (having a market cap of Rs 9643.35 Crore) operating in Hospitals & Allied Services sector.
Krishna Institute of Medical Sciences Ltd. key Products/Revenue Segments include Income from Hospitality, Pharmaceutical Products and Other Operating Revenue for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 500.85 Crore, up 31.62 % from last quarter Total Income of Rs 380.53 Crore and up 4.90 % from last year same quarter Total Income of Rs 477.45 Crore. Company reported net profit after tax of Rs 79.24 Crore in latest quarter.
Investment Rationale
The Orthopedics wing of Sunshine continues to deliver stellar performance. It is expected that the remaining 3 quarters will see steady growth and helps to increase revenue and PAT for FY 23.
Promoter/FII Holdings
Promoters held 38.84 per cent stake in the company as of 30-Jun-2022, while FIIs owned 8.36 per cent, DIIs 22.78 per cent.
The current market price of Ltd. is Rs 1204.1.
Time period given by analyst is one year when Krishna Institute of Medical Sciences Ltd. price can reach defined target.
Krishna Institute of Medical Sciences Ltd., incorporated in the year 1973, is a Small Cap company (having a market cap of Rs 9643.35 Crore) operating in Hospitals & Allied Services sector.
Krishna Institute of Medical Sciences Ltd. key Products/Revenue Segments include Income from Hospitality, Pharmaceutical Products and Other Operating Revenue for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 500.85 Crore, up 31.62 % from last quarter Total Income of Rs 380.53 Crore and up 4.90 % from last year same quarter Total Income of Rs 477.45 Crore. Company reported net profit after tax of Rs 79.24 Crore in latest quarter.
Investment Rationale
The Orthopedics wing of Sunshine continues to deliver stellar performance. It is expected that the remaining 3 quarters will see steady growth and helps to increase revenue and PAT for FY 23.
Promoter/FII Holdings
Promoters held 38.84 per cent stake in the company as of 30-Jun-2022, while FIIs owned 8.36 per cent, DIIs 22.78 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Experience Your Economic Times Newspaper, The Digital Way!
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by